Glioblastoma
Conditions
Keywords
Malignant Gliomas, Immunotherapy
Brief summary
Background: Glioblastoma (GBM) refers to a specific kind of brain cancer called glioblastoma. The standard treatment for GBM is radiation plus temozolomide, an oral chemotherapy drug. Pembrolizumab is an immune therapy that is now used to treat other cancers. The addition of pembrolizumab to the standard treatment of radiation and temozolomide has been shown to be well tolerated. Researchers want to see if adding a vaccine made from the person's own tumor will improve the effect of the pembrolizumab. The vaccine which is developed from fresh tumor taken at the time of surgery is called heat shock protein peptide complex-96 (HSPPC-96). Objectives: To see if the adding of pembrolizumab and HSPPC-96 improves the standard treatment for glioblastoma. Eligibility: Adults at least 18 years old with glioblastoma. Design: Participants will be screened with typical cancer tests: Brain scan Medical history Blood and urine tests Questions about quality of life and symptoms These tests will be repeated throughout the study. Participants will have surgery to remove their tumor. A tissue sample from the tumor will be sent to a lab. A vaccine will be made from it. Some participants will get pembrolizumab and vaccine. Some will get pembrolizumab and placebo. Participants will not know which they get. Participants will get radiation for 6 weeks. Participants will take temozolomide by mouth before each treatment. Participants will get pembrolizumab by intravenous (IV) for 30 minutes 3 times over the radiation cycle. Participants will keep taking the 2 drugs every few weeks for about a year. Some may take pembrolizumab for an additional year. Most participants will get the vaccine or placebo after radiation. They will get it 5 times over 6 weeks. Some participants will continue to get the vaccine every few weeks for 1 or 2 years. Participants will repeat the screening tests when they stop study treatment. They will also have follow-up phone calls.
Detailed description
Background: * Malignant gliomas are unfortunately, in most cases, a uniformly fatal tumor. Despite aggressive surgery, radiation treatment (RT) and chemotherapy at initial diagnosis these tumors almost always recur. * Many clinical trials in glioblastoma (GBM) have evaluated the addition of agent(s) to standard therapy which consists of concurrent radiation with temozolomide chemotherapy after maximal surgical resection in patients with newly diagnosed disease and salvage chemotherapy with either rechallenge with temozolomide or an alternative alkylating agent such as lomustine (CCNU) or cisplatin. To date, none of the combination strategies have demonstrated clinical benefit. Furthermore, in subjects with an unmethylated MGMT (O6-methylguanine-DNA methyltransferase) promoter temozolomide has only modest benefit and salvage therapies have not demonstrated a significant impact in this subject group underscoring the need for more research. * Immunotherapy offers the promise of improving outcomes for patients with GBM by evoking specific immune responses that may produce a more sustained and less toxic effect than conventional therapy. Heat-shock proteins (HSPs), which function as intracellular chaperones, can be used to deliver a variety of tumor antigens to antigen presenting cells for immune stimulation. * Heat Shock Protein-Peptide Complex-96 (HSPPC-96) consists of the heat shock protein glycoprotein-96 (HSP gp-96) and a wide array of chaperoned proteins, including autologous antigenic peptides (aka vaccine). Heat shock proteins (HSP) are molecules that respond to cellular stress and counteract abnormal protein folding. They are known to modulate immune responses, especially the HSP gp-96. In a stressful environment, such as a tumor, HSPs are upregulated and highly expressed on tumor cells. This protects the tumor and leads to resistance to therapy. HSP expression is associated with cellular proliferation, apoptosis evasion, tissue invasion, metastasis, and angiogenesis. * Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between Programmed cell death protein 1 (PD-1) and its ligands, programmed death-ligand 1 (PD-L1) and programmed cell death-ligand 2 (PD-L2). Additionally, pembrolizumab is thought to also have activity in the peripherally circulating T-effector cells by reversing lymphocyte exhaustion. It is currently Food and Drug Administration (FDA) approved for use in patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor and non-small cell lung cancer (NSCLC) with elevated PD-L1 in the tumor. recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. It is also FDA approved for use with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1 and for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. * This study will be the first to evaluate this combination of vaccine (HSPPC-96) and PD-1 inhibition (pembrolizumab) in newly diagnosed GBM patients whose tumors are MGMT promoter unmethylated and are isocytrate dehydrogenase (IDH) wildtype; and will provide important data on immune-modulatory effect of this combination. This may be of particular value in patients with high peripheral PD-L1 expression, but also the value of PD-1 added to standard GBM therapy. As vaccine needs to be generated from the patient s tumor, patients will need to be identified prior to surgery. Eligibility: * MRI findings consistent with a suspected GBM or histologically confirmed newly diagnosed GBM that has not been treated and would benefit from further surgical resection. * Tumor must be supratentorial. * GBM diagnosis must be made by surgical excision (stereotactic biopsy will not be allowed unless there is plan for second surgery to remove greater than or equal to 80% of the tumor) and patients tumors must not have O6-Methylguanine-deoxyribonucleic acid (DNA) Methyltransferase (MGMT) promoter methylation and must be isocitrate Dehydrogenase (IDH) wildtype. * No prior treatment with radiation or chemotherapy for their GBM. * Age greater than or equal to 18 years on day of signing informed consent Objective: \- The primary endpoint is to determine whether the one-year overall survival (OS) rate is improved in newly diagnosed GBM patients whose tumors have an unmethylated MGMT promoter and are IDH wildtype treated with radiation therapy (RT) + temozolomide (TMZ) + Pembrolizumab followed by TMZ + Pembrolizumab + HSPPC-96 vaccine or Placebo vaccine x 6 cycles (1 cycle is 9 weeks). Design: * This will be a randomized, double blind phase II trial of surgery, RT + TMZ + Pembrolizumab followed by TMZ + Pembrolizumab +/- HSPPC-96 in newly diagnosed GBM patients whose tumors have an unmethylated MGMT promoter and are IDH wildtype. * Subjects will be assigned to intervention based on ability to generate vaccine as follows: * If \>= 80 % of tumor removed, \>=7 g of tumor is resected but HSPPC-96 cannot be generated, subjects will be treated on the ancillary arm of RT+TMZ +Pembrolizumab followed by TMZ+ Pembrolizumab. * If\>= 80% of contrasting enhanced tumor removed (based on T1 Post contrast magnetic resonance imaging (MRI) using cross sectional measurement), \>= 7 g of tumor is resected and sufficient HSPPC-96 is generated, subjects will be included in the main cohort and will be randomized on a 1:1 basis to receive: * RT+TMZ +Pembrolizumab followed by TMZ+Pembrolizumab + Placebo OR \--- RT+TMZ +Pembrolizumab followed by TMZ+Pembrolizumab+HSPPC-96 -Subjects whose tumor does not meet the criteria (unmethylated MGMT promoter and IDH wildtype by pathology) and for whom \< 80 % of tumor is removed or \< 7g of tumor is resected are not eligible for further intervention. Approximately 8 potentially eligible patients are screened per month, and it is anticipated that at least 1-2 per month will be accrued per site.
Interventions
DRUGPembrolizumab
Pembrolizumab at 200mg will be administered on day 1 as a 30-minute intravenous (IV) infusion (prior to radiation therapy (RT) every 3 weeks during RT on days 1, 22 and 43. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with heat shock protein peptide complex -96 (HSPPC 96) or placebo vaccine if any is available.
BIOLOGICALHSPPC-96
One week post RT, patients will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
DRUGTemozolomide
Temozolomide (TMZ) will be administered on day 1 of radiation therapy (before radiation therapy (RT) treatment) and continue throughout RT at the dose of 75 mg/m\^2. Post RT: The starting TMZ dose will be 150 mg/m\^2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m\^2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles.
OTHERPlacebo
One week post radiation therapy (RT), participants will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of Temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
PROCEDURESurgery
Tissue for vaccine production and neo-epitope monitoring.
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: Pre-Surgery (Step 1) Inclusion: * Magnetic resonance imaging (MRI) findings consistent with a suspected glioblastoma (GBM) or a histologically confirmed newly diagnosed GBM that has not been treated and would benefit from further surgical resection. As vaccine needs to be generated from the patient's tumor, patients will need to be identified prior to definitive surgery. * Preliminary assessment by the neurosurgeons that \>80% of the tumor can be resected with an expectation that \>7gm of tissue would be resected * Age greater than or equal to 18 years on day of signing informed consent. * Karnofsky performance status greater than or equal to 70. * Tumor must be supratentorial only. * Stereotactic biopsy will not be allowed unless there is plans for second surgery to remove greater than or equal to 80 % of the tumor. * No prior treatment with radiation or chemotherapy for their GBM. * No prior treatment with carmustine (Gliadel) wafers. Post-Surgery (Step 2) Inclusion: * Pathology must be a GBM, O6-methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT) promoter region determined to be unmethylated and isocitrate Dehydrogenase (IDH) wild type greater than or equal to 80 % resection of contrast enhanced tumor on post operative MRI and greater than 7 grams of tumor resected are required otherwise patient is ineligible. * Treatment must be initiated greater than or equal to 14 days and \< 6 weeks from surgery. * Craniotomy site must be adequately healed and free of drainage or cellulitis, and the underlying cranioplasty must appear intact at the time of radiation. Radiation must start within 6 weeks of surgery. * Dexamethasone dose should be less than or equal to 4 mg/day or steroid equivalent prior to starting treatment. If higher doses are needed, consult with Study Chair. * Female subjects of childbearing potential should have a negative urine or serum pregnancy within 7 days prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a negative serum pregnancy test will be required. * Patients must have adequate organ and bone marrow function within 14 days prior to step 2 registration, as defined below: * Absolute neutrophil count (ANC) \> 1.5 x10(9)/L; platelet count \> 100 x 10(9)/L; and hemoglobin (Hb) \>9.0 g/dL within 7 days prior to step 2 registration. Note: The use of transfusion or other intervention to achieve Hb greater than or equal to 9.0 g/dL is acceptable. * Total bilirubin \< 1.5 x ULN (except in patients diagnosed with Gilbert's disease) * Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT) serum glutamate-pyruvate transaminase (SGPT), and alkaline phosphatase (ALP) \< 2.5 x ULN * Serum creatinine \< 1.5 x ULN * International normalized ratio (INR), prothrombin time (PT), or activated partial thromboplastin time (APTT) as follows: In the absence of therapeutic intent to anticoagulate the patient: INR \< 1.5 or PT \< 1.5 x ULN or aPTT \< 1.5 x ULN. In the presence of therapeutic intent to anticoagulate the patient: INR or PT and aPTT within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose of anticoagulants for at least 2 weeks before registration. * Females of child-bearing potential (FOCBP) and males must agree to use two adequate contraception methods (give examples, e.g., hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 120 days following completion of therapy. Should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Male patients who father a child should notify the treating physician. NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: 1. Has not undergone a hysterectomy or bilateral oophorectomy 2. Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \> 12 months) * Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study. * Diagnosis must be made by surgical excision. * Patients should not be on antibiotics for any infection, but post operative antibiotics are allowed if used prophylactically but should be completed prior to starting RT.
Exclusion criteria
Pre-Surgery (Step 1) Exclusion: * Known history of immunodeficiency (HIV). This medical entity can be exacerbated by programmed cell death protein 1 (PD-1) blockade. * History of another malignancy in the previous 3 years, with a disease-free interval of \< 3 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy. Patients who have undergone a bone marrow or stem-cell transplant for any malignancy are excluded. * Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires chronic systemic steroids or immunosuppressive agents except as noted above. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections will not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgren's syndrome will not be excluded from the study. * Has a history of interstitial lung disease, non-infectious pneumonitis, or pneumonitis. * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. Examples include: * Hypertension (defined as 160/95) that is not controlled on medication * Ongoing or active infection requiring systemic treatment * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Psychiatric illness/social situations or substance abuse disorders that would limit compliance with study requirements * Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints. * Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment. * The effects of pembrolizumab and HSPPC-96 on the developing human fetus are unknown. For this reason and because checkpoint inhibitors and immunotherapeutic vaccines as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. * Has received prior therapy with an anti-PD-1, anti-programmed death-ligand 1 (PD-L1), anti-PD-L2, anti-4-1BB (CD137), or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). * On treatment for Hepatitis B or Hepatitis C or history of tuberculosis (TB). * Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Pembrolizumab are not eligible. Known hypersensitivity to any excipients of Pembrolizumab. Post-Surgery (Step 2) Exclusion: * Patients are ineligible if the tumor is not a GBM, MGMT promoter region determined to be unmethylated and IDH wild type, or if \< 80 % resection of contrast enhanced tumor on post-operative MRI or \< 7 grams of tumor is resected. * Patients who are receiving any other investigational agents. * Known history of immunodeficiency (HIV). This medical entity can be exacerbated by PD-1 blockade. * Any form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment excluding steroids. Attempts should be made to have patient on lowest possible dose of steroids. These medical entities can be exacerbated by PD-1 blockade. * History of another malignancy in the previous 3 years, with a disease-free interval of \< 3 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy. Patients who have undergone a bone marrow or stem-cell transplant for any malignancy are excluded. * Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires chronic systemic steroids or immunosuppressive agents except as noted above. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections will not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study. * Has a history of interstitial lung disease, non-infectious pneumonitis, or pneumonitis. * Has an active infection requiring systemic antibiotics within 10 days of surgery. * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. Examples include: * Hypertension (defined as 160/95) that is not controlled on medication * Ongoing or active infection requiring systemic treatment * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Psychiatric illness/social situations or substance abuse disorders that would limit compliance with study requirements * Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints. * Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment. * The effects of pembrolizumab and HSPPC-96 on the developing human fetus are unknown. For this reason and because checkpoint inhibitors and immunotherapeutic vaccines as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. * Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti- Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). * On treatment for Hepatitis B or Hepatitis C or history of TB. * Has received a live vaccine within 30 days prior to the first dose of trial treatment * Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Pembrolizumab are not eligible. Known hypersensitivity to any excipients of Pembrolizumab.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| One-year Overall Survival (OS) Rate | One year | One-year overall survival (OS) rate is defined as the percentage of participants who from time of registration survived to one year in newly diagnosed O6-methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT) unmethylated Glioblastoma (GBM) participants treated with radiation therapy (RT) + Temozolomide (TMZ) + Pembrolizumab followed by Pembrolizumab + TMZ +/- heat-shock protein peptide complex-96 (HSPPC-96) x 6 cycles (1 cycle is 9 weeks) months. Rate of OS is measured by Kaplan-Meier method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response Rate | After treatment, up to 26 months | Response was determined by the Response Assessment in Neuro-Oncology Criteria (RANO) criteria and reported with 95% confidence intervals using exact binomial probability distributions. Complete response is no T1 gadolinium enhancing disease or stable or decreasing T2/fluid-attenuated inversion recovery (FLAIR). Partial response is ≥ 50% decrease in T1 gadolinium enhancing disease or stable or decreasing T2/FLAIR. Stable disease is \<50% decrease but \<25% increase in T1 gadolinium enhancing disease or stable or decreasing T2/FLAIR. Progressive disease is ≥25% incT1 gadolinium enhancing disease, appearance of new lesions or increase in T2/FLAIR. |
| Overall Survival (OS) | Time from registration to the time of death or off study up to 26 months | OS is defined as the time from registration to the time of death. Kaplan-Meier curves will be used to analyze overall survival. |
| Overall Survival at 6, 12 and 24 Months, Post-registration | 6, 12 and 24 months, post-registration | Participants who are alive at 6, 12 and 24 months, post-registration determined from the level of the Kaplan-Meier curves at these time points. |
| Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Start of treatment until participant is off study, approximately 61.5 months | Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. And Grade 5 is death related to adverse event. |
| Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Start of treatment until participant is off study, approximately 61.5 months | Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. And Grade 5 is death related to adverse event. |
| Mean Symptom Severity Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | Baseline, end of treatment or discontinuation, and 30 days after last dose | To evaluate the occurrence of symptoms and correlate to disease progression and tolerance to treatment using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). Participants rate their symptoms on a questionnaire using an 11-point scale (0-10). 0 is not present and 10 is as bad as you can imagine. Differences of at least 2 points will be classified as the minimum clinically meaningful change in the symptom severity measures. Higher score indicates worse severity. |
| Mean Symptom Interference Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | Baseline, end of treatment or discontinuation, and 30 days after last dose | To evaluate the occurrence of symptoms and correlate to disease progression and tolerance to treatment using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). Participants rate their symptoms on a questionnaire using an 11-point scale (0-10) of how much symptoms interfered with different aspects of a patient's life in the last 24 hours such as general activity, mood, work, relations with other people, walking and enjoyment of life. 0 is not present and 10 is as bad as you can imagine. Differences of at least 2 points will be classified as the minimum clinically meaningful change in the symptom severity measures. |
| Percentage of Participants Rating Their Symptom Severity to Be 5 or Greater (on a 0-10) Scale Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) | Baseline, end of treatment or discontinuation, and 30 days after last dose | Percentage of participants rating their symptom severity to be 5 or greater (on a 0-10) scale using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). Participants rate their symptoms on a questionnaire using an 11-point scale (0-10). 0 is not present and 10 is as bad as you can imagine. |
| Progression Free Survival (PFS) | Time from registration to the time of confirmed progression, an average of 9 months | PFS is defined as the time from registration to the time of confirmed progression. Progression was measured by the immunotherapy response assessment for neuro-oncology (iRANO) criteria. Progressive disease is ≥25% increase in the sum of bi-perpendicular diameters of enhancing disease or new lesions or significant worsened T2/fluid-attenuated inversion recovery (FLAIR) or significant clinical decline. |
| Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Start of treatment until participant is off study, approximately 61.5 months | Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. And Grade 5 is death related to adverse event. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | Date treatment consent signed to date off study, approximately 61.5 months. | Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Vaccine Radiation therapy (RT)+Temozolomide (TZ)+Pembrolizumab+Heat Shock Protein Peptide Complex-96.(HSPPC-96). Pembrolizumab at 200mg will be administered on day 1 as a 30-minute intravenous (IV) infusion (prior to radiation therapy during RT phase) every 3 weeks on days 1, 22 and 43. Post RT, participants continue on Pembrolizumab 200mg on day 1 as a 30-minute IV infusion every 3 weeks on days 1, 22, and 43. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 vaccine if any is available. One week post RT, patients will receive weekly x 4 a dose of HSPPC-96 0.4mL intradermal vaccine. HSPPC-96 vaccine will then be given 21 days after the day 5 dose of temozolomide. HSPPC-96 vaccine will be given for 6 cycles or until supply runs out. At one year, if patients are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 if any is available. Temozolomide: TMZ will be administered on day 1 of radiation therapy (before RT treatment) and continue throughout RT at the dose of 75 mg/m\^2. Post RT: The starting TMZ dose will be 150 mg/m\^2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m\^2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles. | 8 |
| Placebo Radiation therapy (RT)+Temozolomide (TZ)+Pembrolizumab+Placebo Vaccine. Pembrolizumab at 200mg will be administered on day 1 as a 30-minute intravenous (IV) infusion (prior to radiation therapy during RT phase) every 3 weeks on days 1, 22 and 43. Post RT, participants continue on Pembrolizumab 200mg on day 1 as a 30-minute IV infusion every 3 weeks on days 1, 22, and 43. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with placebo vaccine if any is available. One week post RT, patients will receive weekly x 4 a dose of placebo vaccine. Placebo vaccine will then be given 21 days after the day 5 dose of temozolomide. Placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if patients are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with placebo vaccine if any is available. Temozolomide: TMZ will be administered on day 1 of radiation therapy (before RT treatment) and continue throughout RT at the dose of 75 mg/m\^2. Post RT: The starting TMZ dose will be 150 mg/m\^2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m\^2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles. | 9 |
| Ancillary Treatment Radiation therapy (RT) + Temozolomide (TMZ) + Pembrolizumab. Pembrolizumab at 200mg will be administered on day 1 as a 30-minute intravenous (IV) infusion (prior to radiation therapy during RT phase) every 3 weeks on days 1, 22 and 43. Post RT, participants continue on Pembrolizumab 200mg on day 1 as 30-minute IV infusion every 3 weeks on days 1, 22, and 43. After completion of 6 cycles, participants may continue on Pembrolizumab for an additional 12 months if felt to be of benefit by the treating physician. Temozolomide: TMZ will be administered on day 1 of radiation therapy (before RT treatment) and continue throughout RT at the dose of 75 mg/m\^2. Post RT: The starting TMZ dose will be 150 mg/m\^2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m\^2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles. | 15 |
| Enrolled But Not Treated Participants were enrolled but not treated. | 58 |
| Total | 90 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Chose treatment outside of UNC | 0 | 0 | 0 | 1 |
| Overall Study | Participant declined to participate (before treatment started) | 0 | 0 | 0 | 3 |
| Overall Study | Participants withdrew consent before surgery. | 0 | 0 | 0 | 1 |
| Overall Study | Participant withdrew consent. | 0 | 0 | 1 | 0 |
| Overall Study | Participant withdrew consent for personal reasons. | 0 | 0 | 1 | 0 |
| Overall Study | Physician Decision | 0 | 0 | 0 | 1 |
| Overall Study | Screen failures | 0 | 0 | 0 | 51 |
| Overall Study | Switched to alternative treatment. | 0 | 0 | 1 | 0 |
| Overall Study | Unable to comply with protocol requirements | 1 | 1 | 0 | 1 |
Baseline characteristics
| Characteristic | Vaccine | Placebo | Ancillary Treatment | Enrolled But Not Treated | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 5 Participants | 2 Participants | 5 Participants | 22 Participants | 34 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants | 7 Participants | 10 Participants | 36 Participants | 56 Participants |
| Age, Continuous | 64 years STANDARD_DEVIATION 11.88 | 58.34 years STANDARD_DEVIATION 12.6 | 58.65 years STANDARD_DEVIATION 8.76 | 59.05 years STANDARD_DEVIATION 14.71 | 59.9 years STANDARD_DEVIATION 10.64 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants | 8 Participants | 14 Participants | 57 Participants | 86 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 2 Participants | 3 Participants | 6 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 1 Participants | 8 Participants | 10 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) White | 8 Participants | 7 Participants | 12 Participants | 45 Participants | 72 Participants |
| Region of Enrollment United States | 8 participants | 9 participants | 15 participants | 58 participants | 90 participants |
| Sex: Female, Male Female | 1 Participants | 2 Participants | 6 Participants | 29 Participants | 38 Participants |
| Sex: Female, Male Male | 7 Participants | 7 Participants | 9 Participants | 29 Participants | 52 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 6 / 8 | 4 / 9 | 10 / 15 | 0 / 58 |
| other Total, other adverse events | 8 / 8 | 9 / 9 | 12 / 15 | 2 / 58 |
| serious Total, serious adverse events | 6 / 8 | 4 / 9 | 8 / 15 | 2 / 58 |
Outcome results
Primary
One-year Overall Survival (OS) Rate
One-year overall survival (OS) rate is defined as the percentage of participants who from time of registration survived to one year in newly diagnosed O6-methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT) unmethylated Glioblastoma (GBM) participants treated with radiation therapy (RT) + Temozolomide (TMZ) + Pembrolizumab followed by Pembrolizumab + TMZ +/- heat-shock protein peptide complex-96 (HSPPC-96) x 6 cycles (1 cycle is 9 weeks) months. Rate of OS is measured by Kaplan-Meier method.
Time frame: One year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Vaccine | One-year Overall Survival (OS) Rate | 52.5 percentage of participants |
| Placebo | One-year Overall Survival (OS) Rate | 71.4 percentage of participants |
| Ancillary Treatment | One-year Overall Survival (OS) Rate | 42.3 percentage of participants |
Secondary
Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab
Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. And Grade 5 is death related to adverse event.
Time frame: Start of treatment until participant is off study, approximately 61.5 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccine | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 2 | 17 Adverse Events |
| Vaccine | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 5 | 0 Adverse Events |
| Vaccine | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 3 | 18 Adverse Events |
| Vaccine | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 4 | 1 Adverse Events |
| Placebo | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 5 | 0 Adverse Events |
| Placebo | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 3 | 25 Adverse Events |
| Placebo | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 2 | 43 Adverse Events |
| Placebo | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 4 | 5 Adverse Events |
| Ancillary Treatment | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 3 | 7 Adverse Events |
| Ancillary Treatment | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 2 | 13 Adverse Events |
| Ancillary Treatment | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 5 | 0 Adverse Events |
| Ancillary Treatment | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 4 | 2 Adverse Events |
| Probably Related | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 4 | 0 Adverse Events |
| Probably Related | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 3 | 3 Adverse Events |
| Probably Related | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 2 | 0 Adverse Events |
| Probably Related | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 5 | 0 Adverse Events |
| Definitely Related | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 5 | 0 Adverse Events |
| Definitely Related | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 2 | 2 Adverse Events |
| Definitely Related | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 3 | 2 Adverse Events |
| Definitely Related | Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 4 | 1 Adverse Events |
Secondary
Mean Symptom Interference Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT).
To evaluate the occurrence of symptoms and correlate to disease progression and tolerance to treatment using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). Participants rate their symptoms on a questionnaire using an 11-point scale (0-10) of how much symptoms interfered with different aspects of a patient's life in the last 24 hours such as general activity, mood, work, relations with other people, walking and enjoyment of life. 0 is not present and 10 is as bad as you can imagine. Differences of at least 2 points will be classified as the minimum clinically meaningful change in the symptom severity measures.
Time frame: Baseline, end of treatment or discontinuation, and 30 days after last dose
Population: There are different numbers for overall participants analyzed because we don't have that data available (i.e., a few participants didn't do a baseline questionnaire).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Vaccine | Mean Symptom Interference Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | Baseline | 2.9 Score on a scale | Standard Deviation 2.4 |
| Vaccine | Mean Symptom Interference Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | End of treatment or discontinuation | 7.0 Score on a scale | Standard Deviation 4 |
| Placebo | Mean Symptom Interference Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | 30 days after last dose | 6.0 Score on a scale | — |
| Placebo | Mean Symptom Interference Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | Baseline | 1.9 Score on a scale | Standard Deviation 1.4 |
| Placebo | Mean Symptom Interference Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | End of treatment or discontinuation | 1.6 Score on a scale | Standard Deviation 2.8 |
| Ancillary Treatment | Mean Symptom Interference Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | Baseline | 2.2 Score on a scale | Standard Deviation 2.7 |
| Ancillary Treatment | Mean Symptom Interference Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | End of treatment or discontinuation | 4.3 Score on a scale | Standard Deviation 4.1 |
| Ancillary Treatment | Mean Symptom Interference Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | 30 days after last dose | 3.1 Score on a scale | Standard Deviation 2.9 |
Secondary
Mean Symptom Severity Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT).
To evaluate the occurrence of symptoms and correlate to disease progression and tolerance to treatment using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). Participants rate their symptoms on a questionnaire using an 11-point scale (0-10). 0 is not present and 10 is as bad as you can imagine. Differences of at least 2 points will be classified as the minimum clinically meaningful change in the symptom severity measures. Higher score indicates worse severity.
Time frame: Baseline, end of treatment or discontinuation, and 30 days after last dose
Population: There are different numbers for overall participants analyzed because we don't have that data available (i.e., a few participants didn't do a baseline questionnaire).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Vaccine | Mean Symptom Severity Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | End of treatment or discontinuation | 4.0 Score on a scale | Standard Deviation 1.5 |
| Vaccine | Mean Symptom Severity Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | Baseline | 1.4 Score on a scale | Standard Deviation 0.8 |
| Placebo | Mean Symptom Severity Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | End of treatment or discontinuation | 1.4 Score on a scale | Standard Deviation 0.8 |
| Placebo | Mean Symptom Severity Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | 30 days after last dose | 1.7 Score on a scale | — |
| Placebo | Mean Symptom Severity Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | Baseline | 1.3 Score on a scale | Standard Deviation 0.9 |
| Ancillary Treatment | Mean Symptom Severity Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | End of treatment or discontinuation | 2.4 Score on a scale | Standard Deviation 1.8 |
| Ancillary Treatment | Mean Symptom Severity Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | 30 days after last dose | 1.9 Score on a scale | Standard Deviation 0.5 |
| Ancillary Treatment | Mean Symptom Severity Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). | Baseline | 1.2 Score on a scale | Standard Deviation 1.1 |
Secondary
Overall Survival at 6, 12 and 24 Months, Post-registration
Participants who are alive at 6, 12 and 24 months, post-registration determined from the level of the Kaplan-Meier curves at these time points.
Time frame: 6, 12 and 24 months, post-registration
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccine | Overall Survival at 6, 12 and 24 Months, Post-registration | 12 months post registration | 52.5 Percentage of participants |
| Vaccine | Overall Survival at 6, 12 and 24 Months, Post-registration | 6 months post registration | 87.5 Percentage of participants |
| Vaccine | Overall Survival at 6, 12 and 24 Months, Post-registration | 24 months post registration | 17.5 Percentage of participants |
| Placebo | Overall Survival at 6, 12 and 24 Months, Post-registration | 12 months post registration | 71.4 Percentage of participants |
| Placebo | Overall Survival at 6, 12 and 24 Months, Post-registration | 6 months post registration | 100.0 Percentage of participants |
| Placebo | Overall Survival at 6, 12 and 24 Months, Post-registration | 24 months post registration | 14.3 Percentage of participants |
| Ancillary Treatment | Overall Survival at 6, 12 and 24 Months, Post-registration | 6 months post registration | 84.6 Percentage of participants |
| Ancillary Treatment | Overall Survival at 6, 12 and 24 Months, Post-registration | 24 months post registration | 10.6 Percentage of participants |
| Ancillary Treatment | Overall Survival at 6, 12 and 24 Months, Post-registration | 12 months post registration | 42.3 Percentage of participants |
Secondary
Overall Survival (OS)
OS is defined as the time from registration to the time of death. Kaplan-Meier curves will be used to analyze overall survival.
Time frame: Time from registration to the time of death or off study up to 26 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Vaccine | Overall Survival (OS) | 14.4 Months |
| Placebo | Overall Survival (OS) | 14.1 Months |
| Ancillary Treatment | Overall Survival (OS) | 10.1 Months |
Secondary
Percentage of Participants Rating Their Symptom Severity to Be 5 or Greater (on a 0-10) Scale Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)
Percentage of participants rating their symptom severity to be 5 or greater (on a 0-10) scale using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). Participants rate their symptoms on a questionnaire using an 11-point scale (0-10). 0 is not present and 10 is as bad as you can imagine.
Time frame: Baseline, end of treatment or discontinuation, and 30 days after last dose
Population: There are different numbers for overall participants analyzed because we don't have that data available (i.e., a few participants didn't do a baseline questionnaire).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccine | Percentage of Participants Rating Their Symptom Severity to Be 5 or Greater (on a 0-10) Scale Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) | Baseline | 38 Percentage of participants |
| Vaccine | Percentage of Participants Rating Their Symptom Severity to Be 5 or Greater (on a 0-10) Scale Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) | End of treatment or discontinuation | 83 Percentage of participants |
| Placebo | Percentage of Participants Rating Their Symptom Severity to Be 5 or Greater (on a 0-10) Scale Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) | Baseline | 63 Percentage of participants |
| Placebo | Percentage of Participants Rating Their Symptom Severity to Be 5 or Greater (on a 0-10) Scale Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) | 30 days after last dose | 100 Percentage of participants |
| Placebo | Percentage of Participants Rating Their Symptom Severity to Be 5 or Greater (on a 0-10) Scale Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) | End of treatment or discontinuation | 100 Percentage of participants |
| Ancillary Treatment | Percentage of Participants Rating Their Symptom Severity to Be 5 or Greater (on a 0-10) Scale Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) | Baseline | 54 Percentage of participants |
| Ancillary Treatment | Percentage of Participants Rating Their Symptom Severity to Be 5 or Greater (on a 0-10) Scale Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) | End of treatment or discontinuation | 83 Percentage of participants |
| Ancillary Treatment | Percentage of Participants Rating Their Symptom Severity to Be 5 or Greater (on a 0-10) Scale Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) | 30 days after last dose | 100 Percentage of participants |
Secondary
Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab
Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. And Grade 5 is death related to adverse event.
Time frame: Start of treatment until participant is off study, approximately 61.5 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccine | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 3 | 8 Adverse events |
| Vaccine | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 5 | 0 Adverse events |
| Vaccine | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 2 | 5 Adverse events |
| Vaccine | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 4 | 0 Adverse events |
| Placebo | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 2 | 19 Adverse events |
| Placebo | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 3 | 5 Adverse events |
| Placebo | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 5 | 0 Adverse events |
| Placebo | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 4 | 0 Adverse events |
| Ancillary Treatment | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 3 | 1 Adverse events |
| Ancillary Treatment | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 5 | 0 Adverse events |
| Ancillary Treatment | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 2 | 11 Adverse events |
| Ancillary Treatment | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 4 | 0 Adverse events |
| Probably Related | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 3 | 7 Adverse events |
| Probably Related | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 2 | 4 Adverse events |
| Probably Related | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 4 | 1 Adverse events |
| Probably Related | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 5 | 0 Adverse events |
| Definitely Related | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 3 | 1 Adverse events |
| Definitely Related | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 2 | 2 Adverse events |
| Definitely Related | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 4 | 1 Adverse events |
| Definitely Related | Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 5 | 0 Adverse events |
Secondary
Progression Free Survival (PFS)
PFS is defined as the time from registration to the time of confirmed progression. Progression was measured by the immunotherapy response assessment for neuro-oncology (iRANO) criteria. Progressive disease is ≥25% increase in the sum of bi-perpendicular diameters of enhancing disease or new lesions or significant worsened T2/fluid-attenuated inversion recovery (FLAIR) or significant clinical decline.
Time frame: Time from registration to the time of confirmed progression, an average of 9 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Vaccine | Progression Free Survival (PFS) | 13.7 Months |
| Placebo | Progression Free Survival (PFS) | 8.0 Months |
| Ancillary Treatment | Progression Free Survival (PFS) | 10.3 Months |
Secondary
Response Rate
Response was determined by the Response Assessment in Neuro-Oncology Criteria (RANO) criteria and reported with 95% confidence intervals using exact binomial probability distributions. Complete response is no T1 gadolinium enhancing disease or stable or decreasing T2/fluid-attenuated inversion recovery (FLAIR). Partial response is ≥ 50% decrease in T1 gadolinium enhancing disease or stable or decreasing T2/FLAIR. Stable disease is \<50% decrease but \<25% increase in T1 gadolinium enhancing disease or stable or decreasing T2/FLAIR. Progressive disease is ≥25% incT1 gadolinium enhancing disease, appearance of new lesions or increase in T2/FLAIR.
Time frame: After treatment, up to 26 months
Population: 4 out of 8 participants in vaccine group were evaluable for response. 6 out of the 9 participants in the placebo group were evaluable for response. 7 out of the 15 ancillary participants were evaluable for response.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccine | Response Rate | Stable Disease | 100.0 percentage of participants |
| Vaccine | Response Rate | Partial Response | 0 percentage of participants |
| Vaccine | Response Rate | Complete Response | 0 percentage of participants |
| Vaccine | Response Rate | Progressive Disease | 0 percentage of participants |
| Placebo | Response Rate | Stable Disease | 100.0 percentage of participants |
| Placebo | Response Rate | Partial Response | 0 percentage of participants |
| Placebo | Response Rate | Progressive Disease | 0 percentage of participants |
| Placebo | Response Rate | Complete Response | 0 percentage of participants |
| Ancillary Treatment | Response Rate | Progressive Disease | 57.1 percentage of participants |
| Ancillary Treatment | Response Rate | Partial Response | 14.3 percentage of participants |
| Ancillary Treatment | Response Rate | Stable Disease | 28.6 percentage of participants |
| Ancillary Treatment | Response Rate | Complete Response | 0 percentage of participants |
Secondary
Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab
Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. And Grade 5 is death related to adverse event.
Time frame: Start of treatment until participant is off study, approximately 61.5 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccine | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 3 | 8 adverse events |
| Vaccine | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 5 | 1 adverse events |
| Vaccine | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 2 | 14 adverse events |
| Vaccine | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 4 | 1 adverse events |
| Placebo | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 2 | 28 adverse events |
| Placebo | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 3 | 13 adverse events |
| Placebo | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 5 | 0 adverse events |
| Placebo | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 4 | 1 adverse events |
| Ancillary Treatment | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 4 | 0 adverse events |
| Ancillary Treatment | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 2 | 10 adverse events |
| Ancillary Treatment | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 3 | 3 adverse events |
| Ancillary Treatment | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 5 | 0 adverse events |
| Probably Related | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 3 | 0 adverse events |
| Probably Related | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 2 | 0 adverse events |
| Probably Related | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 4 | 0 adverse events |
| Probably Related | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 5 | 0 adverse events |
| Definitely Related | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 3 | 0 adverse events |
| Definitely Related | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 2 | 0 adverse events |
| Definitely Related | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 5 | 0 adverse events |
| Definitely Related | Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab | Grade 4 | 0 adverse events |
Other Pre-specified
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: Date treatment consent signed to date off study, approximately 61.5 months.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Vaccine | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 8 Participants |
| Placebo | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 9 Participants |
| Ancillary Treatment | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 15 Participants |
| Probably Related | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 2 Participants |